Loading…
National Prostate Cancer Plan Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
National Prostate Cancer Plan Act Establishes in the Department of Health and Human Services (HHS) the National Prostate Cancer Council on Screening, Early Detection, Assessment, and Monitoring of Prostate Cancer to: (1) develop and implement a strategic plan for the accelerated development of diagnostic tools for prostate cancer, (2) review the effectiveness of diagnostic tools for prostate cancer, (3) coordinate prostate cancer research and services across federal agencies, (4) evaluate all active federal prostate cancer programs, and (5) ensure the inclusion of men at high risk for prostate cancer in clinical, research, and service efforts. Directs the Council to submit annual reports. Requires the first report to include recommendations based on an evaluation of prostate cancer research and gaps in the development and validation of diagnostic tools for prostate cancer. Requires subsequent reports to include an outline for a national research plan, roles for specified agencies, an analysis of the disparities in the incidence and mortality of prostate cancer in high-risk men, and a review of the progress towards the realization of the strategic plan. Terminates the Council on December 31, 2020.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2015 · second_quarter · Health Issues
H.R. 1270, Restoring Access to Medication Act of 2015, all provisions S. 709, Restoring Access to Medication Act of 2015, all provisions H.R. 2652, Protecting Patients and Physicians Against Coding Act of 2015, all provisions H.R. 2730, National Prostate Cancer Plan Act, all provisions S. 216, National Prostate Cancer Plan Act, all provisions S. 222, National Prostate Cancer Plan Act, all provisions S. 1198, Improving the Integrity of Disability Evidence Act, all provisions H.R. 2126, Cutting Costly Codes Act of 2015, all provisions H.R. 6, 21st Century Cures Act, provisions relating to interoperability, registries, and data exchanges H.R.270 - Flexibility in Health IT Reporting (Flex-IT) Act of 2015, all provisions H.R. 2247, ICD-TEN Act, all provisions H.R. 293, To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes, all provisions S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act, all provisions Affordable Care Act implementation Drug Quality and Security Act implementation In-office ancillary services exception Drug Compounding Health Savings Accounts - Prescription requirements for OTC medications Indian Health Services - Purchased/Referred Care program Interstate Medical Licensure Compact/Telemedicine Immigration Laboratory Developed Tests (LDTs) NIH Funding for innovation Prescription drug abuse E-prescribing of controlled substances DEA registration process Opioid Misuse Telemedicine Health Information Technology/Meaningful Use FDA regulation of powdered caffeine Cybersecurity FDA/NIH Modernization Clinical Laboratory Improvement Act (CLIA) modernization Hazardous drugs - handling in healthcare settings National Pain Strategy Pre-diabetes Hypertension HIPAA Administrative simplification (ICD-10, EFT, virtual credit cards) ICD-10 transition
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $5,680,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office
2015 · second_quarter · Health Issues
H.R. 1270, Restoring Access to Medication Act of 2015, all provisions S. 709, Restoring Access to Medication Act of 2015, all provisions H.R. 2652, Protecting Patients and Physicians Against Coding Act of 2015, all provisions H.R. 2730, National Prostate Cancer Plan Act, all provisions S. 216, National Prostate Cancer Plan Act, all provisions S. 222, National Prostate Cancer Plan Act, all provisions S. 1198, Improving the Integrity of Disability Evidence Act, all provisions H.R. 2126, Cutting Costly Codes Act of 2015, all provisions H.R. 6, 21st Century Cures Act, provisions relating to interoperability, registries, and data exchanges H.R.270 - Flexibility in Health IT Reporting (Flex-IT) Act of 2015, all provisions H.R. 2247, ICD-TEN Act, all provisions H.R. 293, To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes, all provisions S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act, all provisions Affordable Care Act implementation Drug Quality and Security Act implementation In-office ancillary services exception Drug Compounding Health Savings Accounts - Prescription requirements for OTC medications Indian Health Services - Purchased/Referred Care program Interstate Medical Licensure Compact/Telemedicine Immigration Laboratory Developed Tests (LDTs) NIH Funding for innovation Prescription drug abuse E-prescribing of controlled substances DEA registration process Opioid Misuse Telemedicine Health Information Technology/Meaningful Use FDA regulation of powdered caffeine Cybersecurity FDA/NIH Modernization Clinical Laboratory Improvement Act (CLIA) modernization Hazardous drugs - handling in healthcare settings National Pain Strategy Pre-diabetes Hypertension HIPAA Administrative simplification (ICD-10, EFT, virtual credit cards) ICD-10 transition
Client expense: $12,400,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office
2015 · second_quarter · Health Issues
S. 222 (National Prostate Cancer Plan Act), all provisions
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2015 · second_quarter · Medicare/Medicaid
in-office ancillary services exception (IOASE) / self-referral issue; meaningful use stage 2 & 3; SGR repeal - H.R. 2, Medicare Access & CHIP Reauthorization Act of 2015; S. 222, National Prostate Cancer Plan Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Medicare/Medicaid
in-office ancillary services exception (IOASE) / self-referral issue; meaningful use stage 2 & 3; SGR repeal - H.R. 2, Medicare Access & CHIP Reauthorization Act of 2015; S. 222, National Prostate Cancer Plan Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE